Gene polymorphisms in the dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) genes and structural modelling of the dhps gene in Colombian isolates of Toxoplasma gondii;Polimorfismos en los genes de dihidrofolato-reductasa (dhfr) y dihidropteroato-sintasa (dhps) y modelado estructural del gen dhps en aislamientos colombianos de Toxoplasma gondii

Biomedica

Volumn 34, Issue 4, 2014, Pages 556-566

  Cortés, Liliana Jazmín ^a   Duque, Sofía ^a   López, Miryam Consuelo ^b   Moncada, Diego ^c   Molina, Diego ^c   Gómez Marín, Jorge Enrique ^c   Gunturiz, María Luz ^a  

^a INSTITUTO NACIONAL DE SALUD   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c UNIVERSIDAD DEL QUINDÍO   (Colombia)

Author keywords

Drug resistance; Folic acid antagonists and inhibitors; Molecular conformation; Polymerase chain reaction; Toxoplasma

Indexed keywords

ESCHERICHIA COLI; TOXOPLASMA; TOXOPLASMA GONDII;

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; PROTOZOAL DNA; PROTOZOAL PROTEIN; RECOMBINANT DNA;

AIDS RELATED COMPLEX; AMINO ACID SUBSTITUTION; ANIMAL; CEREBROSPINAL FLUID; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; COLOMBIA; ENZYMOLOGY; EXON; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PARASITOLOGY; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TOXOPLASMA; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CEREBROSPINAL FLUID; CLONING, MOLECULAR; COLOMBIA; DIHYDROPTEROATE SYNTHASE; DNA, PROTOZOAN; DNA, RECOMBINANT; EXONS; HUMANS; MALE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; PROTOZOAN PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TOXOPLASMOSIS, CEREBRAL;

EID: 84927674922     PISSN: 01204157     EISSN: None     Source Type: Journal    
DOI: 10.7705/biomedica.v34i4.2132     Document Type: Article

References (33)

1. Murat JB, Hidalgo HF, Brenier-Pinchart MP, Pelloux H. Human toxoplasmosis: Which biological diagnostic tests are best suited to which clinical situations? Expert Rev Anti Infect Ther. 2013;11:943-56. http://dx.doi.org/10.1586/14787210.2013.825441
2. Peña YR, Bernal R, Pavía N. Toxoplasmosis diseminada en niños. Informe de dos casos. Enfermedades Infecciosas y Microbiología. 2003:23:149-54.
3. Lindsay D, Blagburn B, Dubey J. Feline toxoplasmosis and the importance of the Toxoplasma gondii oocyst. Parasitology. 1997;19:448-61.
4. Wong SY, Remington JS. Biology of Toxoplasma gondii. AIDS. 1993;7:299-316. http://dx.doi.org/10.1097/00002030-199303000-00001
5. Villena I, Aubert D, Leroux B, Dupouy D, Talmud M, Chemla C, et al. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: Follow-up of 78 cases between 1980 and 1997. Scand J Infect Dis. 1998;30:295-300. http://dx.doi.org/10.1080/00365549850160963
6. Meneceur P, Bouldouyre M, Aubert D, Villena I, Menotti J, Sauvage V, et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone antimicrobial agents and chemotherapy. Antimicrob Agents Chemother. 2008;52:1269-77. http://dx.doi.org/10.1128/AAC.01203-07
7. Lilue J, Müller UB, Steinfeldt T, Howard JC. Reciprocal virulence and resistance polymorphism in the relationship between Toxoplasma gondii and the house mouse. Elife. 2013;2:e01298. http://dx.doi.org/10.7554/eLife.01298
8. Gómez J, Castaño J, Montoya M, Loango N, López C, Sarmiento M, et al. Toxoplasmosis congénita en Colombia: análisis clínico y de laboratorio en 27 casos. Revista de Pediatría. 2000;35:52-7.
9. Gómez J. Tratamiento de la toxoplamosis: esquemas para la forma congénita y en el inmunosuprimido. Rev Salud Pública. 2002;4:35-42.
10. Gómez J, Alvarado F, Hernández C, Cuervo S, Saravia J. Tratamiento de la fase aguda de la toxoplasmosis cerebral con clindamicina-falcidar (pirimetamina-sulfadoxina) en pacientes infectados por VIH. Infectio. 2001;5:163-9.
11. Doliwa C, Xia D, Escotte-Binet S, Newsham EL, Sanya J S, Aubert D, et al. Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE). Int J Parasitol Drugs Drug Resist. 2013 5;3:35-44. http://dx.do/10.1016/j.ijpddr.2012.12.002.eCollection2013
12. Eun J, Ho-Woo N. Changes in enzyme activity and expres-sion of DHRF of Toxoplasma gondii by antifolates. Korean J Parasitol. 1998;6:191-8. http://dx.doi.org/10.3347/kjp.1998.36.3.191
13. Aspinall TV, Joynson DH, Guy E, Hyde JE, Sims PF. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis. J Infect Dis. 2002;185:1637-43. http://dx.doi.org/10.1086/340577
14. Nagamune K, Moreno S, Sibley D. Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis. Antimicrob Agents Chemother. 2007;51:3816-23. http://dx.doi.org/10.1128/AAC.00582-07
15. Katlama C, De Wit S, O'Doherty E, van Glabeke M, Clumeck N. Pyrimethamine-clindamycin Vs. pyrimethamine-sulfadiazine as acute and long term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis. 1996;22:268-75. http://dx.doi.org/10.1093/clinids/22.2.268
16. Schmidt D, Hogh B, Hansen O, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: Tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr. 2006;165:19-25. http://dx.doi.org/10.1007/s00431-005-1665-4
17. Doliwa C, Escotte-Binet S, Aubert D, Sauvage V, Velard F, Schmid A, et al. Sulfadiazine resistance in Toxoplasma gondii: No involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters. Parasite. 2013;20:19. http://dx.doi.org/10.1051/parasite/2013020
18. Donald RGK, Roos DS. Stable molecular transfor-mation of Toxoplasma gondii: A selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria. Proc Natl Acad Sci USA. 1993;90:11703-7. http://dx.doi.org/10.1073/pnas.90.24.11703
19. Reynolds MG, Roos DS. A biochemical and genetic model for parasite resistance to antifolates. Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum. J Biol Chem. 1998; 273:3461-9 http://dx.doi.org/10.1074/jbc.273.6.3461
20. Martín-Hernández I, García-Izquierdo S. Toxoplasmosis: infección oportunista en pacientes con el síndrome de inmunodeficiencia adquirida. Rev Biomed. 2003;14:101-11.
21. de la Torre A, Ríos-Cadavid AC, Cardozo-García CM, Gómez-Marín JE. Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol. 2009;93:1001-4. http://dx.doi.org/10.1136/bjo.2008.155861
22. Galindo J, Cristiano J, Knudson A, Nicholls RS, Guerra A. Mutaciones puntuales en los genes dhfr y dhps de Plasmodium falciparum de tres regiones endémicas para malaria en Colombia. Biomédica. 2010;30:56-64. http://dx.doi.org/10.7705/biomedica.v33i1.643
23. Robles S, Hortúa A, Zimmermann B. Cloning and preliminary characterization of the dihydroorotase from Toxoplasma gondii. Mol Biochem Parasitol. 2006;148:93-8. http://dx.doi.org/10.1016/j.molbiopara.2006.03.003
24. Mejías I, Zimmermann B. Molecular cloning, recombinant expression, and partial characterization of the aspartate transcarbamoylase from Toxoplasma gondii. Mol Biochem Parasitol. 2002;119:191-201. http://dx.doi.org/10.1016/s0166-6851(01)00415-7
25. Cortés LJ, Arévalo A, Sofía D. Aislamiento de Toxoplasma gondii a partir de líquido cefalorraquídeo de dos pacientes VIH positivos. Infectio. 2013;17:61-5. http://dx.doi.org/10.1016/s0123-9392(13)70164-4
26. Wang L, Cheng HW, Huang KQ, Xu YH, Li YN, Du J, et al. Toxoplasma gondii prevalence in food animals and rodents in different regions of China: Isolation, genotyping and mouse pathogenicity. Parasit Vectors. 2013;6:273. http://dx.doi.org/10.1186/1756-3305-6-273
27. Wang L, Chen H, Liu D, Huo X, Gao J, Song X, et al. Genotypes and mouse kit virulence of Toxoplasma gondii isolates from animals and humans in China. PLoS One. 2013;6:e53483. http://dx.doi.org/10.1371/journal.pone.0053483
28. Ponce N, Gómez J. Estandarización y validación clínica de la prueba de reacción en cadena de la polimerasa (PCR) para diagnóstico de toxoplasmosis cerebral en pacientes infectados por el VIH. Infectio. 2003;7:8-14.
29. Chaudary K, Fox B, Bzik D. Comparative aspects of nucleotide and aminoacid metabolism in Toxoplasma gondii and other apicomplexa. In: Louis M, Kami K, editors. Toxoplasma gondii: The model apicomplexan: Perspectives and methods. First edition. Amsterdam: Elsevier Ltda; 2007. p. 465-504. http://dx.doi.org/10.1016/b978-0-12-396481-6.00020-9
30. Wakeley J. The excess of transitions among nucleotide substitutions: New methods of estimating transition bias underscore its significance. Trends Ecol Evol. 1996;11:158-62. http://dx.doi.org/10.1016/0169-5347(96)10009-4
31. Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics. 1998;149:189-202. http://dx.doi.org/10.1186/1475-2875-11-60
32. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94:13944-9. http://dx.doi.org/10.1073/pnas.94.25.13944
33. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 1998;17:3807-15. http://dx.doi.org/10.1093/emboj/17.14.3807